FibromyalgiaIVR-FNCT06948500
Effectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients
A study testing Immersive Virtual Reality and Physical Activity in people with Fibromyalgia, run by Cardenal Herrera University at 1 site in Spain.
Trial summary
The primary aim of this randomized controlled trial is to determine the efficacy of a 6-week immersive virtual reality (IVR)-based therapeutic exercise intervention, which manipulates visual proprioceptive input during exercise, for patients diagnosed with fibromyalgia (FM). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Fibromyalgia
- What is being tested?
- Immersive Virtual Reality and Physical Activity
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteSpain
- Study dates
- 5 May 2025to 10 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults diagnosed with fibromyalgia according to any of the classification criteria established by the American College of Rheumatology (ACR), including those from 1990, 2010, 2011, or 2016;
- Ability to communicate effectively with the research staff;
- A self-reported pain intensity score of ≥3 on a 11-point Numerical Pain Rating Scale (NRS-11).
Who cannot join
- Presence of comorbidities and/or symptoms that constitute a contraindication for immersive virtual reality or exercise-based interventions;
- Presence of medical conditions that may interfere with study outcomes, such as visual, auditory, perceptual, or sensory disorders;
- Use of medications that could potentially affect study results;
- Engagement in another therapeutic physical activity program during the intervention period, or any modifications to existing therapies (including medication or physical therapy) throughout the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Juan Fco. Lisón
Valencia, Valencia-valència, 46006
JUAN JOSÉ AMER-CUENCA, PhD, 961369000 ext. 64642, juanjoamer@uchceu.es
About this study
Official title: Effectiveness of an Immersive Virtual Reality-based Therapeutic Exercise Program With Altered Visual Feedback in Patients With Fibromyalgia: A Randomized Controlled Trial
The primary aim of this randomized controlled trial is to determine the efficacy of a 6-week immersive virtual reality (IVR)-based therapeutic exercise intervention, which manipulates visual proprioceptive input during exercise, for patients diagnosed with fibromyalgia (FM). Participants will be randomly allocated into two groups: an experimental group performing therapeutic exercises integrated with IVR featuring modified visual feedback, and a control group executing identical exercises without IVR integration. The primary outcome will assess the impact of fibromyalgia on daily activities, while secondary outcomes will comprehensively evaluate fatigue, sleep quality, severity of fibromyalgia symptoms, health-related quality of life, anxiety and depressive symptoms, fear-avoidance beliefs, pain catastrophizing, kinesiophobia, indicators of central sensitization, lumbar spine flexion and extension range of motion, somatosensory function, body perception distortion, muscle strength of the handgrip and quadriceps, functional mobility, lower limb strength, behavioral regulation concerning exercise adherence, and patient-reported experiences regarding IVR use. This trial seeks to elucidate whether incorporating IVR into therapeutic exercise protocols reduces the impact of fibromyalgia on patients' daily lives and improves physiological, psychological, and physical outcomes compared to traditional exercise approaches without IVR.
Read the detailed description
Fibromyalgia is a chronic and multifactorial condition marked by widespread pain, fatigue, sleep disturbances, and various neurocognitive and psychosomatic symptoms, severely impacting quality of life and increasing healthcare costs. Although therapeutic exercise is a first-line, evidence-based treatment, its implementation is often hindered by low adherence, kinesiophobia, and maladaptive pain beliefs. Immersive virtual reality (IVR) has gained attention as a novel approach to enhance exercise efficacy through sensory immersion, cognitive distraction, and embodiment. Visual feedback manipulation in IVR-such as creating the illusion of reduced movement-has been shown to increase range of motion and engagement without intensifying perceived pain or effort. While non-immersive VR systems have shown benefits in symptom management and adherence, IVR appears to offer superior outcomes via real-time multisensory integration. However, no studies have yet investigated the clinical effects of integrating IVR with altered visual input during therapeutic exercise in FM. This will be a randomized controlled trial evaluating a 6-week IVR-based exercise program that modulates visual input to create the perception of reduced movement in FM patients. The experimental group will be compared to a control group following the same exercise program without IVR. Outcome measures include pain intensity, fatigue, sleep quality, kinesiophobia, functional capacity, symptom severity, and user experience. This study seeks to fill a critical gap in FM rehabilitation by testing whether IVR-enhanced exercise with visual modulation reduces the impact of fibromyalgia on patients' daily lives and improves physiological, psychological, and physical outcomes compared to traditional exercise approaches without IVR.
- Conditions
- Fibromyalgia
- Being tested
- Immersive Virtual Reality, Physical Activity
- Keywords
- Fibromyalgia, Immersive Virtual reality, Exercise, Pain
- Medical subject headings
- Fibromyalgia, Motor Activity, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Immersive Virtual RealityOther
Participants will wear an HTC Vive Pro head-mounted display with waist, hand and foot trackers during 60-min sessions, 2 times/week for 6 weeks (12 sessions). A gender- and skin-tone-matched first-person avatar will be calibrated to the user's anthropometrics and will mirror all real-time movements. Standardised audio instructions will be played through the headset; a virtual mirror will provide visual feedback.
To facilitate lumbar mobility, two sensorimotor illusions will be applied: (1) Flexion illusion: Avatar upper-limb length will be reduced by ≈20%, encouraging greater trunk flexion; (2) Extension illusion: A virtual bar will rise with lumbar extension but will under-represent real movement by ≈10%. Both manipulations will update continuously throughout each repetition. A physiotherapist will supervise every session and will record adverse events.
Physical ActivityOther
Participants will undertake a 6-week therapeutic exercise program, consisting of two sessions per week (12 sessions total), with a primary objective of reducing fibromyalgia's impact on daily life. Each session will involve ten exercises performed in one or two sets each, depending on the week of the protocol. Exercise repetitions and intensity will be individualized using the Borg Rating of Perceived Exertion (RPE) scale (6-20), maintaining an intensity range of RPE 13-17. Specifically, intensity will start at RPE 14 (moderate) in Weeks 1-2, increase to RPE 15 (moderate-high) in Weeks 3-4, and peak at RPE 16 (high) in Weeks 5-6. No external load will be applied during the first three weeks to allow participants to adapt to the program, while progressive resistance will be introduced during the final three weeks according to individual capacity, ensuring a safe and gradual overload.
| Study group | Role | What they receive |
|---|---|---|
| Immersive Virtual Reality + Physical Activity | Experimental | A set of ten therapeutic exercises using IVR will be implemented. These exercises are designed to enhance strength, stability, mobility, and flexibility in the abdomino-lumbo-pelvic region and lower limbs. During each exercise, participants will wear IVR goggles that modify visual proprioceptive feedback by altering the perceived range of movement. Specifically, the visual input provided by the IVR system will create a discrepancy between actual physical movement and perceived motion, allowing participants to visually experience movements differently from reality. Receives: Other: Immersive Virtual Reality; Other: Physical Activity |
| Physical Activity | Active comparator | Control-group participants will perform the same 6-week therapeutic-exercise program as the experimental group; the only difference will be the absence of the IVR. Training methodology, load progression, assessment procedures, and physiotherapist supervision will remain identical, ensuring comparability between groups. Receives: Other: Physical Activity |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fibromyalgia Impact
Measured with Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). This 21-item instrument evaluates physical function (0-30), overall impact (0-20), and symptom severity (0-50), yielding a total score from 0 to 100, with higher scores indicating greater impairment.
Measured: At six weeks
Secondary outcomes (22)
Fatigue
Fatigue will be assessed using the Spanish version of the Multidimensional Fatigue Inventory (MFI-20), a validated 20-item self-report instrument measuring five dimensions: general and physical fatigue, reduced activity and motivation, and mental fatigue. Items are scored on a 5-point Likert scale, yielding total scores from 20 to 100, with higher scores indicating greater fatigue.
Measured: At six weeks
Sleep quality
Measured using the validated Spanish version of the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report measure evaluating sleep over the past month across seven components. Total scores range from 0 to 21, with higher scores indicating poorer sleep.
Measured: At six weeks
Pain distribution
Assessed with the Widespread Pain Index (WPI; 0 - 19), the 19 item body map component of the 2016 ACR Fibromyalgia criteria. Participants mark each anatomical region in which they have experienced pain during the previous week; the total score corresponds to the number of painful sites, ranging from 0 (no pain) to 19 (pain in all sites), with higher scores indicating a wider pain distribution and greater disease burden.
Measured: At six weeks
Symptom severity
Measured with the Symptom Severity Scale (SSS; 0 - 12), the second component of the 2016 ACR Fibromyalgia criteria. Participants rate the severity of fatigue, non-restorative sleep, cognitive problems and extent of additional somatic symptoms on 0 to 3 Likert items (0 = none, 3 = severe). Scores are summed to yield a total ranging from 0 (no symptoms) to 12 (maximal severity), with higher values reflecting a greater symptom severity.
Measured: At six weeks
Change in Fibromyalgia Survey Diagnostic Criteria (FSDC) total score
The FSDC total score will be calculated by summing the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) scores. This yields an aggregate score ranging from 0 to 31, with higher values reflecting a greater overall fibromyalgia symptom burden.
Measured: At six weeks
Health-related quality of life
Measured using the Spanish EQ-5D-5L, a validated self-reported tool measuring five dimensions on five severity levels. Responses yield an index score (-0.5 to 1.0), with lower values indicating worse health, calculated using the Spanish value set.
Measured: At six weeks
Anxiety and depression
Assessed using the Spanish version of the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report tool comprising two subscales, HADS-Anxiety and HADS-Depression, each scored 0-21. Items are rated on a 4-point Likert scale (0-3), with higher scores indicating greater severity.
Measured: At six weeks
Pain catastrophizing
Measured using the Spanish version of the 13-item Pain Catastrophizing Scale (PCS), which evaluates the frequency of catastrophic thoughts and feelings related to pain across three subscales: rumination, magnification, and helplessness. Items are rated from 0 to 4, yielding a total score of 0-52, where higher scores indicate greater catastrophizing.
Measured: At six weeks
Fear-avoidance beliefs
Assessed using the Spanish version of the 16-item Fear-Avoidance Beliefs Questionnaire (FABQ), scored on a 7-point Likert scale (0-6), where higher scores indicate stronger avoidance beliefs.
Measured: At six weeks
Kinesiophobia
Assessed using the Spanish version of the Tampa Scale for Kinesiophobia (TSK-11), an 11-item self-report measure of fear of movement and reinjury. Items are scored on a 4-point Likert scale (1-4), with total scores ranging from 11 to 44. Higher scores indicate greater kinesiophobia.
Measured: At six weeks
Central sensitization
Measured using the Central Sensitization Inventory (CSI), a validated 25-item self-report measure assessing symptoms associated with central sensitization. Scores range from 0 to 100, with scores of 40 or higher indicating the presence of a central sensitization syndrome.
Measured: At six weeks
Pressure Pain Threshold
Assessed with a handheld digital algometer (Force One™, Wagner Instruments). Measurements will be taken at two sites: (1) the dorsal surface of the right third finger, midway between the distal and middle interphalangeal joints; and (2) a point 5 cm lateral to the right of the spinous process of the third lumbar vertebra (L3). A 1 cm² rubber tip will apply steadily increasing force until the participant first perceives pain; the force will be recorded in kilograms (kg). Three trials will be performed at each site, with 30 seconds of rest between trials, and the mean of the three readings for each site will be used for analysis. Lower pressure pain threshold (PPT) values (kg) indicate higher pain sensitivity. Higher PPT values indicate lower pain sensitivity.
Measured: At six weeks
Temporal summation of pain
Measured with a handheld digital algometer (Force One™, Wagner Instruments) applied to the dorsal surface of the right third finger. Ten pressure pulses, each rising at 2 kg·s-¹ to the individual's mean pressure pain threshold, will be delivered at 1 Hz. Participants will rate pain intensity on a 0-10 verbal Numeric Rating Scale after the first and tenth pulses. The temporal summation (TS) score is calculated as NRS₁₀ - NRS₁ (range: -10 to +10), with positive values indicating temporal summation of pain, a marker of central sensitization.
Measured: At six weeks
Conditioned pain modulation
Assessed with a cuff-induced ischemic stimulus on the left upper arm. The cuff is inflated at 20 mm Hg·s-¹ until the first pain sensation, held for 30 seconds, then adjusted to maintain a pain intensity of 3/10 on the Numeric Rating Scale (NRS), and kept inflated. While the cuff remains on, a digital algometer delivers 10 pressure pulses to the dorsal surface of the right third finger: rising at 2 kg·s-¹ to the site-specific mean pressure pain threshold (PPT), held for 1 second, with 1 second of rest between pulses. Pain intensity is rated (0-10 NRS) after the first and tenth pulses. The conditioned pain modulation (CPM) effect is expressed as NRS₁₀ - NRS₁ (range -10 to +10). Lower or more negative values denote weaker endogenous pain inhibition.
Measured: At six weeks
Lower limb strength and endurance
Assessed using the 30-Second Sit-to-Stand Test (STS-30), a functional test that evaluates lower limb strength and endurance by measuring an individual's ability to repeatedly rise from a chair without upper limb support over a 30-second period. The total number of repetitions performed during the 30-second period serves as an indicator of functional capacity, with higher scores reflecting better performance.
Measured: At six weeks
Functional mobility
Assessed using the Timed Up and Go (TUG) Test, a widely used clinical tool that evaluates gait speed, dynamic balance, and overall functional capacity. Participants are timed while rising from a chair, walking three meters, turning around, walking back, and sitting down. Shorter times indicate better functional performance.
Measured: At six weeks
Isometric quadriceps strength
Measured using a handheld dynamometer, a widely applied tool for quantifying neuromuscular function in individuals with fibromyalgia. The portable device will be placed just above the ankle while the participant is seated with the knee flexed at 90°, in order to measure maximal voluntary isometric contraction (MVIC) of the quadriceps muscle.
Measured: At six weeks
Handgrip strength
Measured with a Jamar hydraulic dynamometer, according to the protocol described by Hamilton et al. Participants will sit with feet flat on the floor, shoulder adducted and neutrally rotated, elbow flexed at 90°, and wrist and forearm in a neutral position. Three maximal trials will be performed with verbal encouragement, with at least 4-minute rest intervals between attempts. The average of the three trials will be used for analysis.
Measured: At six weeks
Behavioral regulations in exercise
Motivational regulation was assessed using the Behavioral Regulation in Exercise Questionnaire-3 (BREQ-3), a 24-item self-report instrument grounded in Self-Determination Theory. Each item is rated on a 5-point Likert scale (0 = "not true for me" to 4 = "very true for me"), producing six subscale scores-Amotivation, External Regulation, Introjected Regulation, Identified Regulation, Integrated Regulation, and Intrinsic Regulation-each ranging from 0 to 16. The total raw score ranges from 0 to 96, with higher values reflecting stronger endorsement of the statements. Depending on the pattern of subscale scores, elevated Intrinsic and Integrated Regulation scores indicate more autonomous motivation, whereas higher External Regulation and Amotivation scores denote more controlled or amotivated regulation.
Measured: At six weeks
Dizziness provoked by immersive virtual-reality
Dizziness will be monitored at every session using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no dizziness" and 10 indicates "worst imaginable dizziness." Dizziness will be captured as a continuous safety outcome, as it is expected to be the most frequent adverse effect of VR. Documenting its intensity will allow for timely adjustments to the intervention protocol. Higher scores will indicate greater levels of dizziness experienced during VR use.
Measured: At six weeks
Change in pain intensity from pre- to post-exercise session (11-point Numeric Rating Scale, 0-10)
Pain intensity will be recorded immediately before and after each exercise session using an 11-point Numeric Rating Scale (NRS-11) ranging from 0 ("no pain") to 10 ("worst imaginable pain"). Participants will be asked: "On a scale from 0 to 10, how intense is your pain right now?". Higher scores indicate greater pain intensity. The outcome will be calculated as the within-session change in pain (post-exercise minus pre-exercise score).
Measured: Immediately before and after each exercise session over the 6-week intervention period (two sessions per week).
Change in total physical activity (MET-minutes/week)
Total weekly physical activity will be estimated using the International Physical Activity Questionnaire - Short Form (IPAQ-SF), a 7-item self-report tool validated in Spanish and recommended by the World Health Organization. Participants report the frequency and duration of walking, moderate, and vigorous physical activities over the previous seven days. Minutes of walking are weighted by 3.3 METs, moderate activity by 4.0 METs, and vigorous activity by 8.0 METs. These values are summed to yield a total MET-minutes-per-week score. The possible range is from 0 to no upper limit; higher values indicate greater energy expenditure.
Measured: At six weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2025
- Study start5 May 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion10 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cardenal Herrera University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Juan F. Lisón Párraga, Dr, Cardenal Herrera University
- Investigators
- Juan F Lisón, PhD, Principal investigator, Cardenal Herrera University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06948500
- Sponsor's protocol ID
- UNIVERSITY CARDENAL HERRERA-80
- Other IDs
- CEEI25/643
- Acronym
- IVR-F
- Status last verified
- Nov 2025
- First submitted
- 10 Apr 2025
- Last updated
- 18 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Salvador-Huerta C, Jordan-Lopez J, Azanon-Nogueira P, Garcia-Lucas C, Amer-Cuenca JJ, Lison JF. Effectiveness of a fully immersive virtual reality-based therapeutic exercise programme with altered visual feedback in patients with fibromyalgia: A study protocol for a randomised controlled trial. PLoS One. 2026 Jun 4;21(6):e0348346. doi: 10.1371/journal.pone.0348346. eCollection 2026.
PubMed 42241401
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of an Immersive Virtual Reality-based Therapeutic Exercise Program With Altered Visual Feedback in Patients With Fibromyalgia: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06948500
- Acronym / sponsor ID
- IVR-F / UNIVERSITY CARDENAL HERRERA-80
- Conditions
- Fibromyalgia
- Keywords
- Fibromyalgia, Immersive Virtual reality, Exercise, Pain
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Cardenal Herrera UniversityUniversity, hospital or other
- Study start
- 5 May 2025 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 10 Feb 2027 (estimated)
- First posted
- 29 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim of this randomized controlled trial is to determine the efficacy of a 6-week immersive virtual reality (IVR)-based therapeutic exercise intervention, which manipulates visual proprioceptive input during exercise, for patients diagnosed with fibromyalgia (FM). Participants will be randomly allocated into two groups: an experimental group performing therapeutic exercises integrated with IVR featuring modified visual feedback, and a control group executing identical exercises without IVR integration. The primary outcome will assess the impact of fibromyalgia on daily activities, while secondary outcomes will comprehensively evaluate fatigue, sleep quality, severity of fibromyalgia symptoms, health-related quality of life, anxiety and depressive symptoms, fear-avoidance beliefs, pain catastrophizing, kinesiophobia, indicators of central sensitization, lumbar spine flexion and extension range of motion, somatosensory function, body perception distortion, muscle strength of the handgrip and quadriceps, functional mobility, lower limb strength, behavioral regulation concerning exercise adherence, and patient-reported experiences regarding IVR use. This trial seeks to elucidate whether incorporating IVR into therapeutic exercise protocols reduces the impact of fibromyalgia on patients' daily lives and improves physiological, psychological, and physical outcomes compared to traditional exercise approaches without IVR.
Detailed description
Fibromyalgia is a chronic and multifactorial condition marked by widespread pain, fatigue, sleep disturbances, and various neurocognitive and psychosomatic symptoms, severely impacting quality of life and increasing healthcare costs. Although therapeutic exercise is a first-line, evidence-based treatment, its implementation is often hindered by low adherence, kinesiophobia, and maladaptive pain beliefs. Immersive virtual reality (IVR) has gained attention as a novel approach to enhance exercise efficacy through sensory immersion, cognitive distraction, and embodiment. Visual feedback manipulation in IVR-such as creating the illusion of reduced movement-has been shown to increase range of motion and engagement without intensifying perceived pain or effort. While non-immersive VR systems have shown benefits in symptom management and adherence, IVR appears to offer superior outcomes via real-time multisensory integration. However, no studies have yet investigated the clinical effects of integrating IVR with altered visual input during therapeutic exercise in FM. This will be a randomized controlled trial evaluating a 6-week IVR-based exercise program that modulates visual input to create the perception of reduced movement in FM patients. The experimental group will be compared to a control group following the same exercise program without IVR. Outcome measures include pain intensity, fatigue, sleep quality, kinesiophobia, functional capacity, symptom severity, and user experience. This study seeks to fill a critical gap in FM rehabilitation by testing whether IVR-enhanced exercise with visual modulation reduces the impact of fibromyalgia on patients' daily lives and improves physiological, psychological, and physical outcomes compared to traditional exercise approaches without IVR.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Immersive Virtual Reality + Physical Activity | Experimental | Other: Immersive Virtual Reality, Other: Physical ActivityA set of ten therapeutic exercises using IVR will be implemented. These exercises are designed to enhance strength, stability, mobility, and flexibility in the abdomino-lumbo-pelvic region and lower limbs. During each exercise, participants will wear IVR goggles that modify visual proprioceptive feedback by altering the perceived range of movement. Specifically, the visual input provided by the IVR system will create a discrepancy between actual physical movement and perceived motion, allowing participants to visually experience movements differently from reality. |
| Physical Activity | Active comparator | Other: Physical ActivityControl-group participants will perform the same 6-week therapeutic-exercise program as the experimental group; the only difference will be the absence of the IVR. Training methodology, load progression, assessment procedures, and physiotherapist supervision will remain identical, ensuring comparability between groups. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults diagnosed with fibromyalgia according to any of the classification criteria established by the American College of Rheumatology (ACR), including those from 1990, 2010, 2011, or 2016;
- Ability to communicate effectively with the research staff;
- A self-reported pain intensity score of ≥3 on a 11-point Numerical Pain Rating Scale (NRS-11).
Key exclusion criteria (4 listed)
- Presence of comorbidities and/or symptoms that constitute a contraindication for immersive virtual reality or exercise-based interventions;
- Presence of medical conditions that may interfere with study outcomes, such as visual, auditory, perceptual, or sensory disorders;
- Use of medications that could potentially affect study results;
- Engagement in another therapeutic physical activity program during the intervention period, or any modifications to existing therapies (including medication or physical therapy) throughout the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Immersive Virtual RealityParticipants will wear an HTC Vive Pro head-mounted display with waist, hand and foot trackers during 60-min sessions, 2 times/week for 6 weeks (12 sessions). A gender- and skin-tone-matched first-person avatar will be calibrated to the user's anthropometrics and will mirror all real-time movements. Standardised audio instructions will be played through the headset; a virtual mirror will provide visual feedback. To facilitate lumbar mobility, two sensorimotor illusions will be applied: (1) Flexion illusion: Avatar upper-limb length will be reduced by ≈20%, encouraging greater trunk flexion; (2) Extension illusion: A virtual bar will rise with lumbar extension but will under-represent real movement by ≈10%. Both manipulations will update continuously throughout each repetition. A physiotherapist will supervise every session and will record adverse events. | Other | Immersive Virtual Reality + Physical Activity |
| Physical ActivityParticipants will undertake a 6-week therapeutic exercise program, consisting of two sessions per week (12 sessions total), with a primary objective of reducing fibromyalgia's impact on daily life. Each session will involve ten exercises performed in one or two sets each, depending on the week of the protocol. Exercise repetitions and intensity will be individualized using the Borg Rating of Perceived Exertion (RPE) scale (6-20), maintaining an intensity range of RPE 13-17. Specifically, intensity will start at RPE 14 (moderate) in Weeks 1-2, increase to RPE 15 (moderate-high) in Weeks 3-4, and peak at RPE 16 (high) in Weeks 5-6. No external load will be applied during the first three weeks to allow participants to adapt to the program, while progressive resistance will be introduced during the final three weeks according to individual capacity, ensuring a safe and gradual overload. | Other | Immersive Virtual Reality + Physical Activity, Physical Activity |
Primary outcome
Fibromyalgia Impact
Time frame: At six weeks
Measured with Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). This 21-item instrument evaluates physical function (0-30), overall impact (0-20), and symptom severity (0-50), yielding a total score from 0 to 100, with higher scores indicating greater impairment.
22 secondary outcomes
Fatigue
Time frame: At six weeks
Sleep quality
Time frame: At six weeks
Pain distribution
Time frame: At six weeks
Symptom severity
Time frame: At six weeks
Change in Fibromyalgia Survey Diagnostic Criteria (FSDC) total score
Time frame: At six weeks
Health-related quality of life
Time frame: At six weeks
Anxiety and depression
Time frame: At six weeks
Pain catastrophizing
Time frame: At six weeks
Fear-avoidance beliefs
Time frame: At six weeks
Kinesiophobia
Time frame: At six weeks
Central sensitization
Time frame: At six weeks
Pressure Pain Threshold
Time frame: At six weeks
Temporal summation of pain
Time frame: At six weeks
Conditioned pain modulation
Time frame: At six weeks
Lower limb strength and endurance
Time frame: At six weeks
Functional mobility
Time frame: At six weeks
Isometric quadriceps strength
Time frame: At six weeks
Handgrip strength
Time frame: At six weeks
Behavioral regulations in exercise
Time frame: At six weeks
Dizziness provoked by immersive virtual-reality
Time frame: At six weeks
Change in pain intensity from pre- to post-exercise session (11-point Numeric Rating Scale, 0-10)
Time frame: Immediately before and after each exercise session over the 6-week intervention period (two sessions per week).
Change in total physical activity (MET-minutes/week)
Time frame: At six weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
- Derived from this study: PubMed 42241401Salvador-Huerta C, Jordan-Lopez J, Azanon-Nogueira P, Garcia-Lucas C, Amer-Cuenca JJ, Lison JF. Effectiveness of a fully immersive virtual reality-based therapeutic exercise programme with altered visual feedback in patients with fibromyalgia: A study protocol for a randomised controlled trial. PLoS One. 2026 Jun 4;21(6):e0348346. doi: 10.1371/journal.pone.0348346. eCollection 2026.
Related trials for Fibromyalgia
Not yet recruitingObservational study
Validity, Reliability, and Clinical Correlates of Immersive Virtual Reality Adaptation of the Five Times Sit-to-stand Test and Timed up and go Tests in Women With Fibromyalgia Syndrome
Fibromyalgia Syndrome
Active, not recruiting
Comparing Instrument-Assisted Soft Tissue Mobilization and Muscle Energy Technique for Myofascial Pain Syndrome in Women
Myofascial Pain Syndrome
Not yet recruitingObservational study
Daily Cognitive Failures and Medication Adherence in Fibromyalgia
Fibromyalgia
Not yet recruiting
Toward Biomarker-Guided Fibromyalgia Treatment With Non-Invasive Vagus Nerve Stimulation
Fibromyalgia
Not yet recruitingObservational study
Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain
Myofascial Pain Syndrome - Neck
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Juan F Lisón, PhD principal investigator
Cardenal Herrera University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Immersive Virtual Reality and Physical Activity in people with Fibromyalgia, run by Cardenal Herrera University at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact JUAN FRANCISCO LISÓN PÁRRAGA, PhD (606503108 ext. 64540, JUANFRAN@UCHCEU.ES), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fibromyalgia Impact (time frame: At six weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06948500, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.